Shandong Weigao Group Medical Polymer Company Limited provided earnings guidance for the six months ended 30 June 2023. For the period, the Company is expected to record a revenue of approximately RMB6,900 million for the Reporting Period, representing a decrease in the range of 1% to 5% as compared with the revenue recognized due to the
accounting restatement as a result of business combination under common control of approximately RMB 7,100 million for the same period last year; and a net profit attributable to
the owners of the Company (excluding extraordinary items) (the "Net Profit") of approximately RMB 1,200 million for the Reporting Period, representing a decrease in the
range of 14% to 19%, as compared with the Net Profit reported with consideration of the accounting restatement as a result of business combination under common control of
approximately RMB1,400 million for the same period last year.